Current job opportunities are posted here as they become available.
The Director of Business Development will drive the growth and sustainability of Conscience’s programs, with a specific focus on engaging academic researchers and technology transfer offices, contract research organizations (CROs), and pharmaceutical companies to engage with, partner, and participate in Conscience programs and funding opportunities. Working closely with the Partnerships Lead, this role will play a pivotal part in advancing Conscience's mission and meeting our organizational goals. This position requires a deep understanding of business principles in drug discovery and development, coupled with exceptional interpersonal and strategic skills.
In the first year, the Director of Business Development will:
Our team works virtually in a remote environment built around daily Slack, Zoom, collaborative docs, and email, along with structured in-person time as needed (regular staff retreats, working meetings). We do not have a central office, though eventually we may add that as part of our work environment. We provide every employee with the essential work tools like a laptop, headset, etc. Remote work allows for some work hour flexibility, which is helpful when managing life commitments and family. Most roles include some travel as needed.
While we’re legally based in Canada, our approach to drug discovery and science is global. We believe that collaboration can happen in every corner of the world, from the most established leaders to also the most unlikely of partners. With that in mind, we invite candidates from a broad range of backgrounds and experiences, including those from historically marginalized or underestimated groups — women, indigenous people, people with disabilities, people of colour, formerly incarcerated people, people who are lesbian, gay, bisexual, transgender, and/or gender nonconforming, first and second generation immigrants, and people from low-income families. A diversity of lived experiences makes our work, and our network community, stronger.
The salary range for this position is $105,000 to $125,000 CAD, to be determined by the successful candidate’s relevant skills, training, and experience. In addition, we offer a competitive benefits package that includes enhanced medical, pharmacare, dental, and disability coverage, along with annual matched RRSP contributions. We provide a minimum of 4 weeks paid vacation annually, plus flexible work hours, as part of a hybrid work environment.
Conscience is a Canadian non-profit based in Toronto, launched with support from the Structural Genomics Consortium, and a $49M grant from the Canadian government. We narrow in on areas of market failure – places where traditional models have left people behind with few options, and not enough support, like rare diseases, antimicrobial resistance, and pandemic preparedness.
Conscience will focus on two things:
Together, we think those two things can make medicines more accessible and affordable.
We’re creating incentives to attract attention and investment in neglected areas that often go unnoticed due to market failures. The end result will be more and faster innovation in AI drug discovery, new medicines, and more equitable access to medicines for everyone, across Canada, and around the world.
The goal of CACHE is to set the stage for a technological breakthrough in computer-based drug design by providing unbiased, high quality experimental feedback on otherwise untested designs from AI experts and computational chemists around the world.
CACHE initiates a new technical drug design challenge every four months to benchmark computational methods. Participants use their computational method to predict molecules that are tested experimentally by CACHE. Each challenge involves two cycles of predictions in order to give participants the opportunity to incorporate learnings from the first round into their designs. At the end of each challenge, CACHE releases all data openly, including chemical structures, to the public.
The Developing Medicines through Open Science (DMOS) program offers support and partnership opportunities for preclinical drug development in disease areas neglected by the pharmaceutical industry, such as orphan diseases and antimicrobial resistance.
This program aims to foster collaborations that undertake preclinical work to develop drug candidates in areas of pharmaceutical market failure, establish proof of concept (POC) for an open science path to drug development and further translate innovations into affordable medicines, generate economic activity, and support small and medium-sized enterprises (SMEs) in Canada.